CARDIFF ONCOLOGY, INC. Restructuring Charges
CARDIFF ONCOLOGY, INC. (CRDF) reported Restructuring Charges of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2020-02-27
- CARDIFF ONCOLOGY, INC. restructuring charges for the quarter ending 2019-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. restructuring charges for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. restructuring charges for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. restructuring charges for the quarter ending 2019-03-31 was $0.00.
- CARDIFF ONCOLOGY, INC. restructuring charges for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CARDIFF ONCOLOGY, INC. restructuring charges for fiscal 2018 was $664.69K, a 69.43% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. restructuring charges for fiscal 2017 was $2.17M, a 175.07% increase from fiscal 2016.
- CARDIFF ONCOLOGY, INC. restructuring charges for fiscal 2016 was $790.44K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $421.35K derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $421.35K derived: sum of 3 quarters · filed 2020-02-27 | $664.69K derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $421.35K derived: sum of 2 quarters · filed 2020-02-27 | $664.69K derived: sum of 3 quarters · filed 2020-02-27 | $664.69K 10-K · filed 2020-02-27 |
| 2018-09-30 | $421.35K 10-Q · filed 2019-11-07 | $664.69K derived: sum of 2 quarters · filed 2019-11-07 | $664.69K 10-Q · filed 2019-11-07 | $1.17M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $243.34K 10-Q · filed 2019-08-08 | $243.34K 10-Q · filed 2019-08-08 | $748.06K derived: sum of 3 quarters · filed 2019-08-08 | $701.59K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $504.73K derived: sum of 2 quarters · filed 2019-03-06 | $458.25K derived: sum of 3 quarters · filed 2019-03-06 | $454.45K derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-12-31 | $504.73K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $458.25K derived: sum of 2 quarters · filed 2019-03-06 | $454.45K derived: sum of 3 quarters · filed 2019-03-06 | $2.17M 10-K · filed 2019-03-06 |
| 2017-09-30 | -$46.47K 10-Q · filed 2018-11-07 | -$50.28K derived: sum of 2 quarters · filed 2018-11-07 | $1.67M 10-Q · filed 2018-11-07 | $2.46M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | -$3.81K 10-Q · filed 2018-08-03 | $1.72M 10-Q · filed 2018-08-03 | $2.51M derived: sum of 3 quarters · filed 2018-08-03 | $2.51M derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | $1.72M 10-Q · filed 2018-05-08 | $2.51M derived: sum of 2 quarters · filed 2018-05-08 | $2.51M derived: sum of 3 quarters · filed 2018-05-08 | $2.51M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $790.44K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $790.44K derived: sum of 2 quarters · filed 2018-02-26 | $790.44K derived: sum of 3 quarters · filed 2018-02-26 | $790.44K 10-K · filed 2018-02-26 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |